Since the last competing renewal, the Hematologic Malignancies and Bone Marrow Transplantation Program, formerly the Leukemia-Lymphoma/BMT Program, has greatly expanded in laboratory based and clinical/'translational research. Multiple Investigators have joined the Program and research projects have been Initiated In leukemia biology (the genomics/ proteomics and epigenetic targeting of leukemia and lymphoma), development of targeted therapies for leukemia, myeloma and lymphoma (epigenetic, MDM- 2, Notch/ ubiquitination and/ kinase pathways) and prevention of relapse after allogeneic BMT, In addition, the cutting edge research in basic biology and outstanding translational efforts in hematopoietic stem cells and graft-versus-host disease after BMT have been further expanded. The amount of peer reviewed funding, both federal and non-federal (Leukemia Lymphoma Society, Damon Runyon, etc.) has substantially increased. Peer-reviewed funding has more than doubled from $5.2 million at the last review to $13.4 million, including $2.8 million in NCI funding, in direct funding. Over this grant period, the 36 members of this program from seven departments have published 177 publications of which 25.4% are intra-programmatic and 37.3% are inter-programmatic. Clinical research has benefitted from the recruitment of prominent clinical investigators leading to an increase in Investigator-generated therapeutic studies, We have also expanded collaborations with industry to study novel drugs. Collectively, these Initiatives are leading to enhanced accrual of patients on clinical trials.

Public Health Relevance

The goal of the Hematologic Malignancies/BMT program is to improve the diagnosis and treatment of blood cancers. Including leukemia, lymphoma, and multiple myeloma through translation of high quality, novel basic and clinical research to benefit patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Skolarus, Ted A; Metreger, Tabitha; Hwang, Soohyun et al. (2017) Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials 18:181
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Pinskey, Justine M; Franks, Nicole E; McMellen, Alexandra N et al. (2017) Neuropilin-1 promotes Hedgehog signaling through a novel cytoplasmic motif. J Biol Chem 292:15192-15204
Maj, Tomasz; Wang, Wei; Crespo, Joel et al. (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332-1341
Zhang, Jie; Feng, Shumei; Su, Wenmei et al. (2017) Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep 7:42819
Mann, J E; Hoesli, R; Michmerhuizen, N L et al. (2017) Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 8:332-344
Birkeland, Andrew C; Foltin, Susan K; Michmerhuizen, Nicole L et al. (2017) Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol 68:5-8
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Chen, Yan; Zhou, Quan; Li, Xue et al. (2017) Ultrasmall Paramagnetic Iron Oxide Nanoprobe Targeting Epidermal Growth Factor Receptor for In Vivo Magnetic Resonance Imaging of Hepatocellular Carcinoma. Bioconjug Chem 28:2794-2803

Showing the most recent 10 out of 1355 publications